Skip to main content
Fig. 5 | Journal of Translational Medicine

Fig. 5

From: Identification of mutation patterns and circulating tumour DNA-derived prognostic markers in advanced breast cancer patients

Fig. 5

Survival analyses of PFS (A) between TNBC patients with low and high ctDNA fractions, (B) between HER2 + patients with low and high bTMB, and (C) between TNBC patients with low and high bTMB. PFS, progression-free survival; TNBC, triple-negative breast cancer; ctDNA, circulating tumour DNA; HER2 + , human epidermal growth factor receptor 2-positive; bTMB, blood-based tumour mutation burden

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us